MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

BACKGROUND: Multiple myeloma (MM) patients with t(14;20) have a poor prognosis and their outcome has not improved following the introduction of bortezomib (Bzb). The mechanism underlying the resistance to proteasome inhibitors (PIs) for this subset of patients is unknown. METHODS: IC50 of Bzb and ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiang, Ya-Wei, Ye, Shiqiao, Huang, Yuhua, Chen, Yu, Van Rhee, Frits, Epstein, Joshua, Walker, Brian A., Morgan, Gareth J., Davies, Faith E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035431/
https://www.ncbi.nlm.nih.gov/pubmed/29980194
http://dx.doi.org/10.1186/s12885-018-4602-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035431/
https://www.ncbi.nlm.nih.gov/pubmed/29980194
http://dx.doi.org/10.1186/s12885-018-4602-4

Ejemplares similares